ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) COO Muthusamy Shanmugam sold 9,520 shares of the stock in a transaction that occurred on Wednesday, April 17th. The shares were sold at an average price of $65.40, for a total transaction of $622,608.00. Following the completion of the sale, the chief operating officer now owns 809,852 shares in the company, valued at $52,964,320.80. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.
Muthusamy Shanmugam also recently made the following trade(s):
- On Monday, April 15th, Muthusamy Shanmugam sold 7,414 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $66.33, for a total transaction of $491,770.62.
- On Thursday, March 7th, Muthusamy Shanmugam sold 15,085 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $66.35, for a total transaction of $1,000,889.75.
- On Tuesday, March 5th, Muthusamy Shanmugam sold 10,093 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $65.35, for a total value of $659,577.55.
- On Monday, January 22nd, Muthusamy Shanmugam sold 5,692 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $55.95, for a total value of $318,467.40.
- On Thursday, January 18th, Muthusamy Shanmugam sold 9,784 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $55.30, for a total value of $541,055.20.
ANI Pharmaceuticals Price Performance
NASDAQ ANIP opened at $65.48 on Thursday. The firm’s 50 day moving average is $64.60 and its 200-day moving average is $58.52. The company has a quick ratio of 2.81, a current ratio of 3.57 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $1.38 billion, a PE ratio of 77.95 and a beta of 0.79. ANI Pharmaceuticals, Inc. has a 12-month low of $36.99 and a 12-month high of $70.81.
Analysts Set New Price Targets
Several brokerages recently issued reports on ANIP. Truist Financial boosted their price objective on ANI Pharmaceuticals from $72.00 to $80.00 and gave the company a “buy” rating in a research report on Friday, March 1st. Guggenheim increased their price objective on shares of ANI Pharmaceuticals from $70.00 to $77.00 and gave the stock a “buy” rating in a research report on Tuesday, March 5th. HC Wainwright boosted their price objective on shares of ANI Pharmaceuticals from $73.00 to $83.00 and gave the company a “buy” rating in a research report on Monday, March 4th. Finally, Capital One Financial started coverage on shares of ANI Pharmaceuticals in a research note on Friday, March 15th. They issued an “overweight” rating and a $80.00 target price for the company. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, ANI Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $80.00.
Read Our Latest Research Report on ANIP
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the stock. China Universal Asset Management Co. Ltd. raised its stake in shares of ANI Pharmaceuticals by 93.6% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 513 shares of the specialty pharmaceutical company’s stock worth $30,000 after purchasing an additional 248 shares in the last quarter. BluePath Capital Management LLC bought a new stake in ANI Pharmaceuticals during the third quarter worth $34,000. Pacer Advisors Inc. acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at $41,000. Point72 Asset Management L.P. lifted its stake in ANI Pharmaceuticals by 60.0% in the second quarter. Point72 Asset Management L.P. now owns 776 shares of the specialty pharmaceutical company’s stock valued at $42,000 after acquiring an additional 291 shares during the last quarter. Finally, Coppell Advisory Solutions LLC bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter valued at about $44,000. 76.05% of the stock is owned by institutional investors and hedge funds.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- How is Compound Interest Calculated?
- United Airlines Soars on Earnings Beat
- What is MarketRank™? How to Use it
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.